Merck Axes Two Cancer Candidates After Disappointing Late
2 days ago · “Considering the totality of the data from the Phase 3 KeyVibe studies, including the efficacy outcomes from KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the Phase 3 KeyVibe-006 trial and other vibostolimab studies,” Merck’s news release stated. Monday’s announcement ends a disappointing run for vibostolimab.
Merck calls quits on two immunotherapies for cancer
4 days ago · According to Merck, emerging findings from trials of vibostolimab and favezelimab led it to scrap each. Following an interim check of two Phase 3 lung cancer studies, trial monitors found the Keytruda-vibostolimab combination met a pre-specified “futility criteria,” meaning patients who’d received it were unlikely to live longer than ...
Merck discontinues clinical development programs for vibostolimab ...
1 day ago · Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody.Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KeyVibe program.. Favezelimab is being evaluated as an investigational ...
Merck Ends Development of Two Experimental Cancer Drugs
2 days ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. ... Merck’s decision to discontinue development on vibostolimab is based on a pre-planned analysis of data from ...
Merck Discontinues Certain Cancer Candidate Trials After Futility
3 days ago · On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational ...
What can we help you find? - Merck
3 days ago · About vibostolimab Vibostolimab (MK-7684) is an investigational humanized anti-TIGIT antibody discovered and developed by Merck. Vibostolimab restores antitumor activity by blocking the TIGIT receptor from binding to its ligands (CD112 and CD155), thereby activating T lymphocytes that help destroy tumor cells. ... This news release of Merck ...
Merck Halts Dosing of Anti-TIGIT Antibody in KeyVibe-010 …
May 14, 2024 · Merck has announced the cessation of dosing its anti-TIGIT antibody, vibostolimab, coformulated with pembrolizumab (Keytruda) in a phase III clinical trial for high-risk melanoma patients.
Vibostolimab/Favezelimab Clinical Programs in …
3 days ago · Clinical development programs including the KeyVibe program investigating the anti–TIGIT antibody vibostolimab and the KEYFORM program investigating the anti–LAG-3 agent favezelimab have been discontinued, according to a press release from the developer, Merck. 1 Data analyses for the phase 3 trials remain ongoing, and results, upon finalization, will be shared with the scientific community.
Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical …
3 days ago · Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and ...
SITC 2024 preview – duelling TIGIT duds | ApexOnco - Clinical …
Nov 4, 2024 · Merck's vibostolimab, given with chemo as part of a fixed-dose combo with pembrolizumab, blew up in first-line SCLC when its Keyvibe-008 trial was halted for futility in August. The SITC late-breaker will thus offer a postmortem, and a particular focus will fall on immune system-mediated adverse events, said to have increased when the Keyvibe ...
- Some results have been removed